Average reduction of ALT levels before therapy and 12 weeks after therapy, 95% CI and p-value according to stage of liver diseases (i.e. either with or without cirrhosis) and outcome of therapy (i.e.: either SVR12 or fail) are reported in Fig. 4b. The gene discussed is GPT; the disease is Cirrhosis.